Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.25 is 29% below its 5-year average of -2.52, near the low end of its 5-year range (-3.69–-0.99).
2.55% above its 12-month average of -3.33.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.62.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 24 comparable quarters.
EARNINGS PER SHARE (EPS)
-3.25
EARNINGS PER SHARE (EPS) AVG TTM
-3.33
EARNINGS PER SHARE (EPS) AVG 3Y
-3.02
EARNINGS PER SHARE (EPS) AVG 5Y
-2.52
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+2.55%
CURRENT VS 3Y AVG
-7.79%
CURRENT VS 5Y AVG
-28.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kymera Therapeutics, Inc.
Market Cap
$8.59B
Earnings Per Share (EPS)
-3.25
TTM Avg
-3.33
3Y Avg
-3.02
5Y Avg
-2.52
Market Cap
$8.75B
Earnings Per Share (EPS)
-2.24
TTM Avg
-2.51
3Y Avg
-2.15
5Y Avg
-1.80
Market Cap
$8.40B
Earnings Per Share (EPS)
1.40
TTM Avg
-0.79
3Y Avg
-1.41
5Y Avg
-1.76
Market Cap
$8.86B
Earnings Per Share (EPS)
1.03
TTM Avg
1.21
3Y Avg
-0.37
5Y Avg
-1.01
Market Cap
$8.99B
Earnings Per Share (EPS)
-3.75
TTM Avg
-4.83
3Y Avg
-4.88
5Y Avg
-4.31
Market Cap
$9.02B
Earnings Per Share (EPS)
N/A
TTM Avg
0.30
3Y Avg
1.38
5Y Avg
1.40
Market Cap
$9.33B
Earnings Per Share (EPS)
N/A
TTM Avg
0.30
3Y Avg
1.38
5Y Avg
1.40
Market Cap
$7.92B
Earnings Per Share (EPS)
0.36
TTM Avg
-1.91
3Y Avg
-1.77
5Y Avg
-0.94
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.59B | -3.25 | -3.33 | -3.02 | -2.52 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.75B | -2.24 | -2.51 | -2.15 | -1.80 |
| Oscar Health, Inc. (OSCR)vs › | $8.40B | 1.40 | -0.79 | -1.41 | -1.76 |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.86B | 1.03 | 1.21 | -0.37 | -1.01 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.99B | -3.75 | -4.83 | -4.88 | -4.31 |
| Bruker Corporation (BRKRP)vs › | $9.02B | N/A | 0.30 | 1.38 | 1.40 |
| Bruker Corporation (BRKR)vs › | $9.33B | N/A | 0.30 | 1.38 | 1.40 |
| Caris Life Sciences, Inc. (CAI)vs › | $7.92B | 0.36 | -1.91 | -1.77 | -0.94 |
| Insulet Corp. (PODD)vs › | $9.38B | 5.35 | 4.74 | 3.13 | 2.14 |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.69B | -12.93 | -11.85 | -27.93 | -45.71 |
Trailing EPS (TTM)
$-3.25
Forward EPS (Est.)
$-3.85
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.69 |
| 2024-12-31 | -2.98 |
| 2023-12-31 | -2.52 |
| 2022-12-31 | -2.87 |
| 2021-12-31 | -2.09 |
| 2020-12-31 | -0.99 |
| 2019-12-31 | -0.93 |
| 2018-12-31 | -0.48 |
